Head-to-Head

Eli Lilly & Co. vs. Theravance Biopharma, Inc.

LLY

Eli Lilly & Co.

$1176.10 -1.12%

VS TBPH

Theravance Biopharma, Inc.

$17.04 +0.06%

Eli Lilly & Co. (LLY) comes out ahead, leading on 5 of 9 compared factors.

Size & Scale

LLYTBPH
Market Cap $1.06 trillion $884.18 million
Revenue (TTM) $79.67 billion $104.31 million
Net Income (TTM) $26.71 billion $53.81 million

LLY leads on 3 of 3 size & scale factors.

Valuation

LLYTBPH
P/E Ratio 39.48 16.87
Price / Book 31.29 3.05
Price / Sales 13.31 8.48

TBPH leads on 3 of 3 valuation factors.

Profitability

LLYTBPH
Net Margin 33.53% 51.58%
Return on Equity 78.84% 18.57%

LLY and TBPH split the profitability factors evenly.

Dividend

LLYTBPH
Dividend Yield 0.59% —
Payout Ratio 23.23 —

LLY and TBPH split the dividend factors evenly.

Risk & Sentiment

LLYTBPH
Short Interest 1.29% 11.71%

LLY leads on 1 of 1 risk & sentiment factors.

Dig deeper: LLY overview, LLY financials, TBPH overview, TBPH financials.

Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.